Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification
May 19, 2023 16:15 ET
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, May 19, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the Company"), a biotech company focused on...
Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
May 17, 2023 09:00 ET
|
Clearmind Medicine Inc.
The conference will stream live on Monday, June 12, at 10:00 AM EST Tel Aviv, Israel / Vancouver, Canada, May 17, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND),...
Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder
May 12, 2023 09:00 ET
|
Clearmind Medicine Inc.
IMCA medical center's ethics committee approves clinical trial using proprietary CMND-100 treatment in Israel Tel Aviv, Israel / Vancouver, Canada, May 12, 2023 (GLOBE NEWSWIRE) -- Clearmind...
Clearmind Medicine Retains Crescendo Communications LLC. for Investor Relations and Announces Granting of Stock and Warrants
May 09, 2023 16:15 ET
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, May 09, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on...
Clearmind Medicine Strengthens Scientific Advisory Board with Appointment of Prof. Joseph Tam
May 08, 2023 08:30 ET
|
Clearmind Medicine Inc.
Hebrew University of Jerusalem professor is an expert on obesity and metabolic syndrome Tel Aviv, Israel / Vancouver, Canada, May 08, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc....
Clearmind Medicine Announces Clinical Supply Agreement for its Upcoming Clinical Trial
May 02, 2023 08:30 ET
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, May 02, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on...
Clearmind Medicine Forms a Data and Safety Monitoring Board to Oversee its First-in-Human Clinical Trial
April 27, 2023 08:30 ET
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, April 27, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on...
Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression
April 21, 2023 08:30 ET
|
Clearmind Medicine Inc.
The application is for a novel psychedelic-based combination, of Clearmind's MEAI and SciSparc's Cannamide™ Tel Aviv, Israel / Vancouver, Canada, April 21, 2023 (GLOBE NEWSWIRE) --...
Clearmind Medicine Engages Experienced Contract Research Organization to Support its First-in-Human Clinical Trial
April 20, 2023 05:37 ET
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, April 20, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on...
Clearmind Medicine Closes US$3.5 Million Public Offering
April 06, 2023 16:15 ET
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, April 06, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on the discovery and...